Virax Biolabs Group (NASDAQ:VRAX) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Virax Biolabs Group (NASDAQ:VRAX) in a research note released on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $3.00 price objective on the stock.

Virax Biolabs Group Stock Down 1.7 %

VRAX opened at $1.14 on Monday. The firm’s fifty day moving average price is $1.63 and its two-hundred day moving average price is $1.89. Virax Biolabs Group has a 1 year low of $0.60 and a 1 year high of $9.00.

Hedge Funds Weigh In On Virax Biolabs Group

A hedge fund recently bought a new stake in Virax Biolabs Group stock. XTX Topco Ltd bought a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,863 shares of the company’s stock, valued at approximately $27,000. XTX Topco Ltd owned approximately 0.37% of Virax Biolabs Group as of its most recent SEC filing. Institutional investors own 8.61% of the company’s stock.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.